Showing results (111-120 of 396) with videos related to
Sort By:
Pageof 40
European Journal of Cancer (Oxford, England : 1990)|July 5, 2021
Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancersDirk Schadendorf, Caroline Robert, Reinhard Dummer, et al.Human Pathology|December 17, 2009
Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarraysJanice M Mehnert, Mary M McCarthy, Lucia Jilaveanu, et al.The Journal of Investigative Dermatology|December 17, 2008
Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomideTobias Sinnberg, Konstantinos Lasithiotakis, Heike Niessner, et al.Journal of Neuro-Oncology|April 13, 2015
Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor eraDaniel A Wattson, Ryan J Sullivan, Andrzej Niemierko, et al.JAMA Oncology|March 10, 2017
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized TrialNaomi B Haas, Judith Manola, Janice P Dutcher, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanomaKeith T Flaherty, Sandra J Lee, Fengmin Zhao, et al.The Journal of Investigative Dermatology|February 9, 2016
Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma SurvivalMi Ryung Roh, Sameer Gupta, Kyu-Hyun Park, et al.AJR. American Journal of Roentgenology|December 21, 2012
MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenibHyunseon Christine Kang, Kay-See Tan, Stephen M Keefe, et al.Investigational New Drugs|December 18, 2009
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trialSimon Pacey, Mark J Ratain, Keith T Flaherty, et al.The Oncologist|June 19, 2015
Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced CancersKeith T Flaherty, Betty K Hamilton, Mark A Rosen, et al.Pageof 40